ORIGINAL ARTICLE: Safety Analysis of the Diaphragm in Combination with Lubricant or Acidifying Microbicide Gels: Effects on Markers of Inflammation and Innate Immunity in Cervicovaginal Fluid
- 11 January 2009
- journal article
- research article
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 61 (2), 121-129
- https://doi.org/10.1111/j.1600-0897.2008.00670.x
Abstract
Objective Diaphragms are being considered for use with vaginal microbicide gels to provide enhanced protection against sexually transmitted pathogens. The purpose of this study was to determine whether use of a diaphragm with microbicide or placebo gel causes cervicovaginal inflammation or perturbations in cervicovaginal immune defense. Method of study Eighty‐one non‐pregnant women were randomized into three groups and instructed to use Milex® (CooperSurgical, Inc., Trumbull, CT, USA)diaphragms overnight for 14 days in combination with one of the two acid‐buffering microbicide gels [ACIDFORM™ (Instead Inc., La Jolla, CA, USA) or BufferGel™ (BG; ReProtect Inc., Baltimore, Maryland)] or placebo gel (K‐Y Jelly®; Personal Products Inc., Raritan, NJ, USA). Cervicovaginal lavages (CVLs) were performed prior to study entry and on days 8 and 16. Nine soluble mediators of vaginal inflammation or immune defense were measured in CVLs by Bio‐Plex or ELISA. Results Use of diaphragms with placebo or microbicide gel was not associated with increased levels of inflammation markers. Concentrations of secretory leukocyte protease inhibitor (SLPI) were markedly reduced in the BG group. Conclusion Daily use of a diaphragm with placebo or acidifying microbicide gel did not cause cervicovaginal inflammation. However, diaphragm/BG use was associated with markedly reduced levels of SLPI, an important mediator of innate immune defense. Further studies are warranted to establish the safety of diaphragm/microbicide gel combinations.Keywords
This publication has 40 references indexed in Scilit:
- Whither or Wither Microbicides?Science, 2008
- Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trialThe Lancet, 2007
- ACIDFORM Inactivates Herpes Simplex Virus and Prevents Genital Herpes in a Mouse Model: Optimal Candidate for Microbicide CombinationsThe Journal of Infectious Diseases, 2006
- Detection of implantation-related cytokines in cervicovaginal secretions and peripheral blood of fertile women during ovulatory menstrual cyclesFertility and Sterility, 2004
- Salivary Secretory Leukocyte Protease Inhibitor Is Associated with Reduced Transmission of Human Immunodeficiency Virus Type 1 through Breast MilkThe Journal of Infectious Diseases, 2002
- Safety and Tolerability of BufferGel, a Novel Vaginal Microbicide, in Women in the United StatesClinical Infectious Diseases, 2001
- The Impact of the Ovulatory Cycle on Cytokine Production: Evaluation of Systemic, Cervicovaginal, and Salivary CompartmentsJournal of Interferon & Cytokine Research, 2000
- Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4 + T CellsScience, 1999
- Repertoire of Chemokine Receptor Expression in the Female Genital Tract: Implications for Human Immunodeficiency Virus TransmissionThe American Journal of Pathology, 1998
- Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8 + T CellsScience, 1995